OverviewSuggest Edit

Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions.  All of the Company's drug candidates are new molecular entities discovered internally by its dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. Lexicon Pharmaceuticals has advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome.

TypePublic
Founded1995
HQThe Woodlands, US
Websitelexpharma.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Feb 2019)202(+17%)
Revenue (FY, 2018)$63.2 M(-30%)
Share Price (Nov 2019)$3.5 (+4%)

Key People/Management at Lexicon Pharmaceuticals

Raymond Debbane

Raymond Debbane

Chairman of the Board
Pablo Lapuerta

Pablo Lapuerta

Executive Vice President of Clinical Development and Chief Medical Officer
Jeffrey L. Wade

Jeffrey L. Wade

Executive Vice President and Chief Financial Officer
James F. Tessmer

James F. Tessmer

Vice President of Finance and Accounting
Alan J. Main

Alan J. Main

Executive Vice President, Commercial Supply Operations
Lonnel Coats

Lonnel Coats

President and Chief Executive Officer and Director
Show more

Lexicon Pharmaceuticals Office Locations

Lexicon Pharmaceuticals has offices in The Woodlands, Atlanta, Birmingham, Boston and in 26 other locations
The Woodlands, US (HQ)
8800 Technology Forest Pl
Atlanta, US
Atlanta, GA, USA
Birmingham, US
Birmingham, AL, USA
Boston, US
Boston, MA, USA
Charlotte, US
Charlotte, NC, USA
Chicago, US
Chicago, IL, USA
Show all (31)

Lexicon Pharmaceuticals Financials and Metrics

Lexicon Pharmaceuticals Revenue

Lexicon Pharmaceuticals's revenue was reported to be $63.21 m in FY, 2018
USD

Revenue (Q2, 2019)

9.7m

Gross profit (Q2, 2019)

8.4m

Gross profit margin (Q2, 2019), %

86.3%

Net income (Q2, 2019)

(23.0m)

EBIT (Q2, 2019)

(18.5m)

Market capitalization (15-Nov-2019)

375.1m

Closing stock price (15-Nov-2019)

3.5

Cash (30-Jun-2019)

11.1m

EV

610.4m
Lexicon Pharmaceuticals's current market capitalization is $375.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.8m1.1m2.2m22.9m130.0m83.3m90.3m63.2m

Revenue growth, %

929%469%(36%)

Cost of goods sold

1.9m2.5m

Gross profit

88.4m60.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

555.0k355.0k300.0k199.0k372.0k360.0k214.0k238.0k277.0k676.0k419.0k1.8m376.0k566.0k12.5m20.1m27.7m18.3m12.1m26.9m25.2m13.8m6.9m9.2m9.7m

Cost of goods sold

225.0k537.0k599.0k533.0k838.0k551.0k553.0k1.3m

Gross profit

18.1m11.5m26.3m24.7m12.9m6.3m8.7m8.4m

Gross profit Margin, %

99%96%98%98%94%92%94%86%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2017FY, 2018

Cash

186.3m30.4m37.5m137.3m46.6m61.7m80.4m

Accounts Receivable

350.0k1.4m790.0k1.0m4.8m5.9m

Prepaid Expenses

3.7m6.3m4.6m4.8m4.4m2.7m

Inventories

1.9m4.7m
Quarterly
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2017FY, 2018

Net Income

(116.2m)(110.2m)(104.1m)(100.3m)(4.7m)(129.0m)(120.5m)

Depreciation and Amortization

4.9m4.2m2.9m1.9m727.0k3.4m3.7m

Inventories

(1.9m)(2.7m)

Accounts Payable

(10.4m)995.0k(18.9m)
USDY, 2019

EV/EBIT

-32.9 x

EV/CFO

-11.6 x

Debt/Equity

-3.8 x

Debt/Assets

1.1 x

Financial Leverage

-3.6 x
Show all financial metrics

Lexicon Pharmaceuticals Operating Metrics

FY, 2016

Phase I Trials Products

1

Phase III Trials Products

2

Preclinical Phase Products

1

Products

1
Show all operating metrics

Lexicon Pharmaceuticals Online and Social Media Presence

Embed Graph

Lexicon Pharmaceuticals News and Updates

Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update

THE WOODLANDS, Texas, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended September 30, 2019.

Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes

Changes in Clinical Biomarkers Suggestive of Favorable Effects on Kidney Function in Patients with Type 1 Diabetes

Lexicon Pharmaceuticals Announces Date Change for Second Quarter 2019 Financial Results Conference Call and Webcast to July 31, 2019

THE WOODLANDS, Texas, July 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has changed the date of its previously announced earnings release, conference call and webcast and will now release financial results for the second quarter of 2019 on Wedn…

Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program

Sanofi Provides Disputed Termination Notice Sanofi Provides Disputed Termination Notice

Lexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update

THE WOODLANDS, Texas, May 01, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended March 31, 2019.

Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes

THE WOODLANDS, Texas, March 22, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that management will conduct a conference call and live webcast today, Friday, March 22, 2019, at 2:45 p.m. EDT (1:45 p.m. CDT) to provide a regulatory update on sotagliflozin, an …
Show more

Lexicon Pharmaceuticals Blogs

Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium

The Woodlands, Texas, October 2, 2019 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from five posters highlighting XERMELO® (telotristat ethyl) will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium (NA…

Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement with Sanofi

Conference Call and Webcast Today at 5:00 pm EDT / 4:00 pm CDT The Woodlands, Texas, September 10, 2019 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of Zynquista™ (sotagliflozin) and the settleme…

Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting

The Woodlands, Texas, September 10, 2019 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that clinical data for Zynquista™ (sotagliflozin) will be presented at the upcoming European Association for the Study of Diabetes (EASD) 55th annual meeting (September 16-20; Barcelona, Spain). …

Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults with Type 1 Diabetes

Changes in Clinical Biomarkers Suggestive of Favorable Effects on Kidney Function in Patients with Type 1 Diabetes Results Recently Published in Diabetes Care The Woodlands, Texas, August 8, 2019 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive 52-week cardiorenal results fro…

Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update

The Woodlands, Texas, July 31, 2019 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2019. “We are pleased that recent preliminary results of three Phase 3 clinical trials support the potential benefit…

Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (sotagliflozin) Type 2 Diabetes Phase 3 Program

Sanofi Provides Disputed Termination Notice The Woodlands, Texas, July 26, 2019 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), received preliminary topline results from Sanofi for three Phase 3 trials of Zynquista™ (sotagliflozin) in adults living with type 2 diabetes from the InSynchrony clinical …
Show more

Lexicon Pharmaceuticals Frequently Asked Questions

  • When was Lexicon Pharmaceuticals founded?

    Lexicon Pharmaceuticals was founded in 1995.

  • Who are Lexicon Pharmaceuticals key executives?

    Lexicon Pharmaceuticals's key executives are Raymond Debbane, Pablo Lapuerta and Jeffrey L. Wade.

  • How many employees does Lexicon Pharmaceuticals have?

    Lexicon Pharmaceuticals has 202 employees.

  • What is Lexicon Pharmaceuticals revenue?

    Latest Lexicon Pharmaceuticals annual revenue is $63.2 m.

  • What is Lexicon Pharmaceuticals revenue per employee?

    Latest Lexicon Pharmaceuticals revenue per employee is $312.9 k.

  • Who are Lexicon Pharmaceuticals competitors?

    Competitors of Lexicon Pharmaceuticals include MannKind Corporation, Ajinomoto Althea and LogicBio Therapeutics.

  • Where is Lexicon Pharmaceuticals headquarters?

    Lexicon Pharmaceuticals headquarters is located at 8800 Technology Forest Pl, The Woodlands.

  • Where are Lexicon Pharmaceuticals offices?

    Lexicon Pharmaceuticals has offices in The Woodlands, Atlanta, Birmingham, Boston and in 26 other locations.

  • How many offices does Lexicon Pharmaceuticals have?

    Lexicon Pharmaceuticals has 31 offices.